{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"169.442","value":"-23.035"},{"groupId":"OG001","spread":"102.661","value":"-18.671"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"446"},{"groupId":"OG001","value":"455"}],"units":"Participants"}],"title":"Day 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"110.364","value":"-58.935"},{"groupId":"OG001","spread":"150.076","value":"-30.908"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"368"},{"groupId":"OG001","value":"367"}],"units":"Participants"}],"title":"Day 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"104.943","value":"-78.411"},{"groupId":"OG001","spread":"125.254","value":"-62.038"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"250"}],"units":"Participants"}],"title":"Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"124.751","value":"-103.789"},{"groupId":"OG001","spread":"159.184","value":"-88.881"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"181"}],"units":"Participants"}],"title":"Day 11"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"110.502","value":"-122.339"},{"groupId":"OG001","spread":"155.762","value":"-112.588"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"221"},{"groupId":"OG001","value":"240"}],"units":"Participants"}],"title":"Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"115.243","value":"-131.333"},{"groupId":"OG001","spread":"268.733","value":"-122.342"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"217"},{"groupId":"OG001","value":"219"}],"units":"Participants"}],"title":"Day 29"}],"denoms":[{"counts":[{"groupId":"OG000","value":"446"},{"groupId":"OG001","value":"455"}],"units":"Participants"}],"description":"Blood to evaluate CRP was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","dispersionType":"Standard Deviation","groups":[{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG000","title":"Remdesivir Plus Baricitinib"},{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG001","title":"Remdesivir Plus Placebo"}],"paramType":"MEAN","populationDescription":"The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.","reportingStatus":"POSTED","timeFrame":"Days 1, 3, 5, 8, 11, 15 and 29","title":"Change From Baseline in C-reactive Protein (CRP)","type":"SECONDARY","unitOfMeasure":"mg/L"}